Formestane Versus Megestrol Acetate in Postmenopausal Breast Cancer Patients After Failure of Tamoxifen: a Phase III Prospective Randomised Cross Over Trial of Second-line Hormonal Treatment (SAKK 2090)

By Swiss Group for Clinical Cancer Research SAKK   Thurlimann B.   Castiglione M.   Hsu-Schmitz S.F.   Cavalli F.   Bonnefoi H.   Fey M.F.   Morant R.   Lohnert T.   Goldhirsch A.  

European Journal of Cancer, Vol. 33, Iss. 7, 1997-06 ,pp. : 1017-1024

Elsevier

Access to resources Recommend Favorite

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

By Thürlimann Beat   Hess Dagmar   Köberle Dieter   Senn Isabella   Ballabeni Pierluigi   Pagani Olivia   Perey Lucien   Aebi Stefan   Rochlitz Christoph   Goldhirsch Aron  

Breast Cancer Research and Treatment, Vol. 85, Iss. 3, 2004-06 ,pp. : 247-254

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group - a nonrandomized pilo

By Sjostrom J.   Blomqvist C.   Mouridsen H.   Pluzanska A.   Ottosson-Lonn S.   Bengtsson N.-O.   Ostenstad B.   Mjaaland I.   Palm-Sjovall M.   Wist E.   Valvere V.   Anderson H.   Bergh J.  

European Journal of Cancer, Vol. 35, Iss. 8, 1999-08 ,pp. : 1194-1201

Elsevier

Access to resources Recommend Favorite

Quality of Life in Postmenopausal Patients with Breast Cancer after Failure of Tamoxifen: Formestane Versus Megestrol Acetate as Second-line Hormonal Treatment

By Bernhard J.   Castiglione-Gertsch M.   Schmitz S.-F.H.   Thurlimann B.   Cavalli F.   Morant R.   Fey M.F.   Bonnefoi H.   Goldhirsch A.   Hurny C.  

European Journal of Cancer, Vol. 35, Iss. 6, 1999-06 ,pp. : 913-920

Elsevier

Access to resources Recommend Favorite

Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

By Andersen Jørn   Kamby Claus   Ejlertsen Bent   Cold Søren   Ewertz Marianne   Jacobsen Erik   Philip Preben   Møller Knud   Jensen Disa   Møller Susanne  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 718-724

Informa Healthcare

Access to resources Recommend Favorite